A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu et al., Cancer Statistics, 2009, CA: A Cancer Journal for Clinicians, vol.59, issue.4, pp.225-274, 2009.
DOI : 10.3322/caac.20006

M. Katz, J. Fleming, J. Lee, and P. Pisters, Current Status of Adjuvant Therapy for Pancreatic Cancer, The Oncologist, vol.15, issue.11, pp.1205-132010, 2010.
DOI : 10.1634/theoncologist.2010-0121

D. Kirn and F. Mccormick, Replicating viruses as selective cancer therapeutics, Molecular Medicine Today, vol.2, issue.12, pp.519-546, 1996.
DOI : 10.1016/S1357-4310(97)81456-6

J. Cornelis, A. Haag, C. Kornfeld, G. Balboni, A. Dege et al., Autonomous parvovirus vectors, Viral Vectors: Basic Science and Gene Therapy, pp.97-118, 2000.

A. Angelova, M. Aprahamian, S. Grekova, A. Hajri, B. Leuchs et al., Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV, Clinical Cancer Research, vol.15, issue.2, pp.511-520, 2009.
DOI : 10.1158/1078-0432.CCR-08-1088

URL : https://hal.archives-ouvertes.fr/pasteur-00748222

S. Grekova, M. Aprahamian, N. Giese, S. Schmitt, T. Giese et al., Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent, Cancer Biology & Therapy, vol.10, issue.12, pp.1280-1289, 2011.
DOI : 10.4161/cbt.10.12.13455

R. Toporovski, M. Morrow, and D. Weiner, Interferons as potential adjuvants in prophylactic vaccines, Expert Opinion on Biological Therapy, vol.160, issue.3, pp.1489-500, 2010.
DOI : 10.1182/blood-2008-11-190520

C. Miller, S. Maher, and H. Young, Clinical Use of Interferon-??, Annals of the New York Academy of Sciences, vol.3, issue.1, pp.69-79, 2009.
DOI : 10.1111/j.1749-6632.2009.05069.x

D. Duluc, M. Corvaisier, S. Blanchard, L. Catala, P. Descamps et al., Interferon-?? reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages, International Journal of Cancer, vol.21, issue.2, pp.367-73, 2009.
DOI : 10.1002/ijc.24401

G. Windbichler, H. Hausmaninger, W. Stummvoll, A. Graf, C. Kainz et al., Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial, Br J Cancer, vol.82, pp.1138-4410735496, 2000.

A. Raitano, P. Scuderi, and M. Korc, Binding and Biological Effects of Tumor Necrosis Factor and Gamma Interferon in Human Pancreatic Carcinoma Cells, Pancreas, vol.5, issue.3, pp.267-77, 1990.
DOI : 10.1097/00006676-199005000-00005

M. Loos, N. Giese, J. Kleeff, T. Giese, M. Gaida et al., Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer, Cancer Letters, vol.268, issue.1, pp.98-109, 2008.
DOI : 10.1016/j.canlet.2008.03.056

G. Beatty, E. Chiorean, M. Fishman, B. Saboury, U. Teitelbaum et al., CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans, Science, vol.331, issue.6024, pp.1612-1618, 2011.
DOI : 10.1126/science.1198443

S. Hirano, T. Etoh, R. Okunaga, K. Shibata, M. Ohta et al., Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model, Oncology Reports, vol.21, issue.6, pp.1381-1385, 2009.
DOI : 10.3892/or_00000364

X. Lun, J. Jang, N. Tang, H. Deng, R. Head et al., Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide, Clinical Cancer Research, vol.15, issue.8, pp.2777-88, 2009.
DOI : 10.1158/1078-0432.CCR-08-2342